About
Our mission is to promote the standardization and scalability of autologous regenerative therapies, making available to physicians Lab-in-a-Box bioengineering systems to carry out these therapies in their own offices in an easy and closed way so that due to their cost-effectiveness, they reach the largest number of patients possible.
Qrem Cytokine, the company's first product to be marketed since 2018, automates and standardizes the production of an Autologous Cytokine-Rich Serum (ACRS) from a patient's blood.
Healthcare professionals can treat various indications requiring tissue repair or regeneration by locally injecting the ACRS into the treatment area.
Qrem is currently working on positioning the product to achieve reimbursement from healthcare systems in Europe and USA and thus grow exponentially. For this reason, it is seeking parters that cooperates in the commercialization and financing the company.
THERAPEUTIC AREA
DermatologyMusculoskeletalObstetrics/GynecologyOrthopedics/Orthopedic SurgeryPodiatryRheumatologyTraumaUrology
VALUE CHAIN
Design / R&D / EngineeringOEM (Original Equipment Manufacturer)Sales & Distribution
INDUSTRIAL BIOTECHNOLOGY
Bioprocesses
LIFE SCIENCE
Therapy and physical medicine
MEDICINE
Medical Technology / Biomedical EngineeringStem cell Technologies